|
|
News Breaks | | | | February 9, 2013 | | 14:51 EDT |  | ARRY, AZN, NVS | Array expects to make progress on generating data on hematology programs
In a press release Array BioPharma said : During 2013, Array (ARRY) expects to make substantial progress in generating data to inform registration study decisions for our wholly-owned hematology programs, ARRY-520 and ARRY-614. Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with Novartis (NVS)). Also, AstraZeneca (AZN) recently announced a potential start of a Phase 3 trial with Array-invented selumetinib in non-small cell lung cancer during the second half of 2013. | |
|
News For ARRY;NVS;AZN From The Last 14 Days Check below for free stories on ARRY;NVS;AZN the last two weeks. |
|
|
| May 20, 2013 | | 07:29 EDT |  | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. | | | May 17, 2013 | | 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
 Subscribe for More Information | | | 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | | | 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. | | | May 16, 2013 | | 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information | | | May 15, 2013 | | 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information | | | 09:51 EDT | | ARRY | Array BioPharma management to meet with Leerink
Meeting to be held in San Francisco on May 17 hosted by Leerink. | | | May 14, 2013 | | 07:24 EDT | | AZN | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | May 13, 2013 | | 16:53 EDT | | AZN | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link | | | | 15:55 EDT | | AZN | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information | | | May 10, 2013 | | 11:48 EDT | | AZN | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information | | | May 9, 2013 | | 10:17 EDT | | AZN | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information | |
|
|
|
|
|
|
